326 related articles for article (PubMed ID: 28065935)
41. Targetable HPMA copolymer-aminohexylgeldanamycin conjugates for prostate cancer therapy.
Borgman MP; Ray A; Kolhatkar RB; Sausville EA; Burger AM; Ghandehari H
Pharm Res; 2009 Jun; 26(6):1407-18. PubMed ID: 19225872
[TBL] [Abstract][Full Text] [Related]
42. Antiangiogenic antitumor activity of HPMA copolymer-paclitaxel-alendronate conjugate on breast cancer bone metastasis mouse model.
Miller K; Eldar-Boock A; Polyak D; Segal E; Benayoun L; Shaked Y; Satchi-Fainaro R
Mol Pharm; 2011 Aug; 8(4):1052-62. PubMed ID: 21545170
[TBL] [Abstract][Full Text] [Related]
43. Comparison of active and passive targeting of doxorubicin for somatostatin receptor 2 positive tumor models by octreotide-modified HPMA copolymer-doxorubicin conjugates.
He S; Zhou Z; Li L; Yang Q; Yang Y; Guan S; Zhang J; Zhu X; Jin Y; Huang Y
Drug Deliv; 2016; 23(1):285-96. PubMed ID: 24865288
[TBL] [Abstract][Full Text] [Related]
44. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
45. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines.
Greco F; Vicent MJ; Penning NA; Nicholson RI; Duncan R
J Drug Target; 2005; 13(8-9):459-70. PubMed ID: 16332571
[TBL] [Abstract][Full Text] [Related]
46. Tumor targeting and microenvironment-responsive multifunctional fusion protein for pro-apoptotic peptide delivery.
Yin J; Liu D; Bao L; Wang Q; Chen Y; Hou S; Yue Y; Yao W; Gao X
Cancer Lett; 2019 Jun; 452():38-50. PubMed ID: 30904618
[TBL] [Abstract][Full Text] [Related]
47. Improved mitochondrial targeting effect of HPMA copolymer by SS20 peptide mediation and nonendocytosis pathway.
Liu Y; Li Q; Xiong X; Zhou Z
J Pept Sci; 2019 Feb; 25(2):e3144. PubMed ID: 30588703
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of primary and metastatic tumors in mice by E-selectin-targeted polymer-drug conjugates.
Shamay Y; Raviv L; Golan M; Voronov E; Apte RN; David A
J Control Release; 2015 Nov; 217():102-12. PubMed ID: 26297207
[TBL] [Abstract][Full Text] [Related]
49. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy.
Jung HK; Kim S; Park RW; Park JY; Kim IS; Lee B
J Control Release; 2016 Aug; 235():259-267. PubMed ID: 27282414
[TBL] [Abstract][Full Text] [Related]
50. A novel α
Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z
J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244
[TBL] [Abstract][Full Text] [Related]
51. A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery.
Zhong J; Li L; Zhu X; Guan S; Yang Q; Zhou Z; Zhang Z; Huang Y
Biomaterials; 2015 Oct; 65():43-55. PubMed ID: 26142775
[TBL] [Abstract][Full Text] [Related]
52. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
53. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
54. An in-tether chiral center modulates the proapoptotic activity of the KLA peptide.
Li J; Hu K; Chen H; Wu Y; Chen L; Yin F; Tian Y; Li Z
Chem Commun (Camb); 2017 Sep; 53(75):10452-10455. PubMed ID: 28884757
[TBL] [Abstract][Full Text] [Related]
55. The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse.
Huang SM; Hsu PC; Chen MY; Li WS; More SV; Lu KT; Wang YC
Int J Cancer; 2012 Aug; 131(3):722-32. PubMed ID: 22015944
[TBL] [Abstract][Full Text] [Related]
56. Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity.
Hao W; Hu C; Huang Y; Chen Y
PLoS One; 2019; 14(11):e0223738. PubMed ID: 31703065
[TBL] [Abstract][Full Text] [Related]
57. An octopus-mimic PEGylated peptide as a specific integrin αvβ3 inhibitor for preventing tumor progression.
Shan X; Zhang L; Xu Y; Sun L; Guo L; Feng S; Ge H; Gu T; Ning X
Chem Commun (Camb); 2020 Feb; 56(14):2178-2181. PubMed ID: 31971174
[TBL] [Abstract][Full Text] [Related]
58. In vitro/vivo evaluation of novel mitochondrial targeting charge-reversal polysaccharide-based antitumor nanoparticle.
Fang L; Lin H; Wu Z; Wang Z; Fan X; Cheng Z; Hou X; Chen D
Carbohydr Polym; 2020 Apr; 234():115930. PubMed ID: 32070547
[TBL] [Abstract][Full Text] [Related]
59. Identification of CD21-binding peptides with phage display and investigation of binding properties of HPMA copolymer-peptide conjugates.
Ding H; Prodinger WM; Kopecek J
Bioconjug Chem; 2006; 17(2):514-23. PubMed ID: 16536485
[TBL] [Abstract][Full Text] [Related]
60. Cardioprotective effects of galectin-3 inhibition against ischemia/reperfusion injury.
Mo D; Tian W; Zhang HN; Feng YD; Sun Y; Quan W; Hao XW; Wang XY; Liu XX; Li C; Cao W; Liu WJ; Li XQ
Eur J Pharmacol; 2019 Nov; 863():172701. PubMed ID: 31568784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
